Literature DB >> 21038378

The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations.

Craig M McDonald1, Erik K Henricson, Jay J Han, R Ted Abresch, Alina Nicorici, Leone Atkinson, Gary L Elfring, Allen Reha, Langdon L Miller.   

Abstract

In this study we used the 6-minute walk distance (6MWD) to characterize ambulation over time in Duchenne/Becker muscular dystrophy (DBMD). The 6MWD was assessed in 18 boys with DBMD and 22 healthy boys, ages 4-12 years, over mean [range] intervals of 58 [39-87] and 69 [52-113] weeks, respectively. Height and weight increased similarly in both groups. At 52 weeks, 6MWD decreased in 12 of 18 (67%) DBMD subjects (overall mean [range]: 357 [125-481] to 300 [0-510] meters; Δ -57 meters, -15.9%), but increased in 14 of 22 (64%) healthy subjects (overall mean [range]: 623 [479-754] to 636 [547-717] meters; Δ +13 meters, +2.1%). Two DBMD subjects lost ambulation. Changes in 6MWD depended on stride length and age; improvements usually occurred by 7-8 years of age; older DBMD subjects worsened, whereas older healthy subjects were stable. The 6MWD changes at 1 year confirm the validity of this endpoint and emphasize that preserving ambulation must remain a major goal of DBMD therapy.

Entities:  

Mesh:

Year:  2010        PMID: 21038378     DOI: 10.1002/mus.21808

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  56 in total

Review 1.  Gene therapy for muscular dystrophy: moving the field forward.

Authors:  Samiah Al-Zaidy; Louise Rodino-Klapac; Jerry R Mendell
Journal:  Pediatr Neurol       Date:  2014-08-07       Impact factor: 3.372

2.  Knee extensor strength exhibits potential to predict function in sporadic inclusion-body myositis.

Authors:  Linda Pax Lowes; Lindsay Alfano; Laurence Viollet; Xiomara Quintero Rosales; Zarife Sahenk; Brian K Kaspar; K Reed Clark; Kevin M Flanigan; Jerry R Mendell; Michael P McDermott
Journal:  Muscle Nerve       Date:  2012-02       Impact factor: 3.217

3.  A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy.

Authors:  Elizabeth M Gibbs; Rachelle H Crosbie-Watson
Journal:  J Vis Exp       Date:  2017-12-29       Impact factor: 1.355

4.  Cross-section and feasibility study on the non-invasive evaluation of muscle hemodynamic responses in Duchenne muscular dystrophy by using a near-infrared diffuse optical technique.

Authors:  Wen-Chin Weng; Jung-Chih Chen; Chia-Yen Lee; Chia-Wei Lin; Wang-Tso Lee; Jeng-Yi Shieh; Chia-Chen Wang; Ching-Cheng Chuang
Journal:  Biomed Opt Express       Date:  2018-09-12       Impact factor: 3.732

5.  Lower leg muscle involvement in Duchenne muscular dystrophy: an MR imaging and spectroscopy study.

Authors:  Martin Torriani; Elise Townsend; Bijoy J Thomas; Miriam A Bredella; Reza H Ghomi; Brian S Tseng
Journal:  Skeletal Radiol       Date:  2011-07-29       Impact factor: 2.199

Review 6.  The role of the neuromuscular medicine and physiatry specialists in the multidisciplinary management of neuromuscular disease.

Authors:  Craig M McDonald; William M Fowler
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-08       Impact factor: 1.784

7.  Exposure-Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy.

Authors:  Xiaonan Li; Laurie S Conklin; John van den Anker; Eric P Hoffman; Paula R Clemens; William J Jusko
Journal:  J Clin Pharmacol       Date:  2020-05-20       Impact factor: 3.126

8.  Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS.

Authors:  Ishu Arpan; Rebecca J Willcocks; Sean C Forbes; Richard S Finkel; Donovan J Lott; William D Rooney; William T Triplett; Claudia R Senesac; Michael J Daniels; Barry J Byrne; Erika L Finanger; Barry S Russman; Dah-Jyuu Wang; Gihan I Tennekoon; Glenn A Walter; H L Sweeney; Krista Vandenborne
Journal:  Neurology       Date:  2014-08-06       Impact factor: 9.910

9.  The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used.

Authors:  Craig M McDonald; Erik K Henricson; R Ted Abresch; Jay J Han; Diana M Escolar; Julaine M Florence; Tina Duong; Adrienne Arrieta; Paula R Clemens; Eric P Hoffman; Avital Cnaan
Journal:  Muscle Nerve       Date:  2013-05-16       Impact factor: 3.217

10.  MRI/MRS evaluation of a female carrier of Duchenne muscular dystrophy.

Authors:  Sean C Forbes; Donovan J Lott; Richard S Finkel; Claudia Senesac; Barry J Byrne; H Lee Sweeney; Glenn A Walter; Krista Vandenborne
Journal:  Neuromuscul Disord       Date:  2012-10-01       Impact factor: 4.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.